Skip to main content
Stacie S. Aarestad

Stacie S. Aarestad

Edwards Wildman Palmer LLP
Partner
Search Me on: Edwards Wildman

Results for: Stacie S. Aarestad

    • Boston Tel +1 617 239 0314 | Fax +1 866 955 8599

    Massachusetts Lawyers Weekly to Honor Stacie Aarestad at ‘Top Women of Law’ Event ...

    Stacie Aarestad is the chair of the Firm’s Securities Offering and Public Company Counseling Practice Group. She focuses her practice on corporate and securities law matters, public company representation and merger and acquisition transactions. She represents issuers in a broad range of capital market transactions, including public and private offerings of debt and equity securities. She also advises companies with respect to tender offers, exchange offers, debt repurchases and stock buybacks. A significant portion of Stacie’s practice includes counseling public company clients on their ongoing reporting obligations, corporate governance and related regulatory matters, including the Sarbanes-Oxley Act of 2002. She also regularly counsels clients with respect to Section 16 matters, insider trading regulations, executive compensation matters and various other matters affecting public companies and their officers and directors.

    Representation of:

    • Enanta Pharmaceuticals, Inc. in its initial public offering of common stock.
    • Dyax Corp. in public securities offerings including:
      • $80,000,000 underwritten public offering of common stock;
      • $65,000,000 underwritten public offering of common stock;
      • $30,000,000 registered direct offering of common stock;
      • $63,537,500 underwritten public offering of common stock;
      • $21,000,000 underwritten public offering of common stock;
      • $17,250,000 underwritten public offering of common stock;
      • $50,000,000 Committed Equity Financing Facility with Azimuth Opportunity Ltd.; and
      • $44,300,000 underwritten public offering of common stock.
    • Dyax Corp. in connection with secured loans including:
      • $65,000,000 loan agreement with Cowen Healthcare Royalty Partners, L.P., consisting of a $50,000,000 Tranche A loan and a $15,000,000 Tranche B loan, secured by Dyax’s phage display Licensing and Funded Research Program; and
      • $30,000,000 royalty interest assignment agreement with Paul Capital Partners.
    • Lamar Advertising Company in high yield and convertible debt offerings and tender offers including:
      • $510,000,000 144A offering of 5 ⅜% Senior Notes due 2024;
      • $535,000,000 144A offering of 5% Senior Subordinated Notes due 2023 with follow-on exchange offer;
      • $500,000,000 144A offering of 5 ⅞% Senior Subordinated Notes due 2022 with follow-on exchange offer;
      • $400,000,000 144A offering of 7 ⅞% Senior Subordinated Notes due 2018 with follow-on exchange offer;
      • Cash Tender Offer and Consent Solicitation for all of Lamar’s then outstanding 7 ¼% Senior Subordinated Notes due 2013;
      • Tender Offer to eligible employees and directors to exchange certain outstanding options to purchase the Company’s Class A common stock for a lesser number of new options;
      • Cash Tender Offers for all of Lamar’s then outstanding 2 ⅞% Convertible Notes due 2010—Series B;
      • $350,000,000 144A offering of 9 ¾% Senior Notes due 2014 with follow-on exchange offer;
      • $275,000,000 144A offering of 6 ⅝% Senior Subordinated Notes due 2015—Series C with follow-on exchange offer;
      • Exchange Offer of a new series of 2 ⅞% Convertible Notes due 2010—Series B for all outstanding 2 ⅞% Convertible Notes due 2010;
      • $216,000,000 144A offering of 6 ⅝% Senior Subordinated Notes due 2015—Series B with follow-on exchange offer; and
      • $400,000,000 144A offering of 6 ⅝% Senior Subordinated Notes due 2015 with follow-on exchange offer.
    • NewStar Financial, Inc. in its $125,000,000 PIPE with institutional investors including, Corsair Capital, Union Square Partners and Och-Ziff Capital Management, Swiss Re and SAB Capital.

    Featured Experience

    • Dyax Corp Public Offering

      Our Business Law lawyers represented Dyax Corp. in its $60,000,000 Public Offering of Common Stock in October 2013. MORE

    • Dyax Corp. Registered Direct Offering

      Our Business Law lawyers represented Dyax Corp. in its $30,000,000 registered direct offering (RDO) to existing institutional investors. MORE

    • Enanta Closes IPO

      In 2013, our Business Law lawyers represented Enanta Pharmaceuticals, in its initial public offering (IPO), which raised $64 million for Enanta's development of new compounds for combination treatment regimens for Hepatitis C.  MORE

    • Dyax Corp. Debt Finance

      Our Business Law lawyers represented Dyax Corp. as the borrower in a $58,740,709 senior secured trache B credit facility from LFRP Investors, L.P. MORE

    • Dyax Corp Public Offering

      Our Business Law lawyers represented Dyax Corp. in its $60,000,000 Public Offering of Common Stock in October 2013. MORE

    • Dyax Corp. Registered Direct Offering

      Our Business Law lawyers represented Dyax Corp. in its $30,000,000 registered direct offering (RDO) to existing institutional investors. MORE

    • Enanta Closes IPO

      In 2013, our Business Law lawyers represented Enanta Pharmaceuticals, in its initial public offering (IPO), which raised $64 million for Enanta's development of new compounds for combination treatment regimens for Hepatitis C.  MORE

    • Lamar Advertising Placement of Subordinated Notes

      In 2012, our Securities lawyers represented Baton Rouge, Louisiana- based Lamar Advertising Company as issuer in the Rule 144A and Reg S Placement of 5% Senior Subordinated Notes due 2023. MORE

    • Dyax Corp. Debt Finance

      Our Business Law lawyers represented Dyax Corp. as the borrower in a $58,740,709 senior secured trache B credit facility from LFRP Investors, L.P. MORE

    • Lamar Advertising Tender Offer

      We represented Lamar Advertising in the 2012 tender offer for up to an aggregate of $700,000,000 6 5/8% Senior Subordinated Notes due 2015, 6 5/8% Senior Subordinated Notes due 2015 - Series B and 6 5/8% Senior Subordinated Notes due 2015 - Series C. MORE

    • Rule 144A and Reg S Placement of 5 7/8% Senior Subordinated Notes Due 2022

      In February 2012, we represented Lamar Advertising as issuer in the Rule 144A and Reg S Placement of 5 7/8% Senior Subordinated Notes due 2022. Baton Rouge-based Lamar is the nation’s leading out-of-home advertising company. MORE

    • Dyax Corp. Registered Direct Offering

      Our Business Law lawyers represented Dyax Corp. in its $30,000,000 registered direct offering (RDO) to existing institutional investors. MORE

    • Enanta Closes IPO

      In 2013, our Business Law lawyers represented Enanta Pharmaceuticals, in its initial public offering (IPO), which raised $64 million for Enanta's development of new compounds for combination treatment regimens for Hepatitis C.  MORE

    • Dyax Corp. Debt Finance

      Our Business Law lawyers represented Dyax Corp. as the borrower in a $58,740,709 senior secured trache B credit facility from LFRP Investors, L.P. MORE

    • Dyax Corp. Debt Finance

      Our Business Law lawyers represented Dyax Corp. as the borrower in a $58,740,709 senior secured trache B credit facility from LFRP Investors, L.P. MORE

    • Lamar Advertising Tender Offer

      We represented Lamar Advertising in the 2012 tender offer for up to an aggregate of $700,000,000 6 5/8% Senior Subordinated Notes due 2015, 6 5/8% Senior Subordinated Notes due 2015 - Series B and 6 5/8% Senior Subordinated Notes due 2015 - Series C. MORE

    Education +-

    Admissions+-

    Memberships+-

    The hiring of a lawyer is an important decision that should not be based solely on advertisements. Prior results do not guarantee a similar outcome.